Connecta Therapeutics Raises €3.1M Seed to Advance Fragile X Syndrome Program

Connecta Therapeutics Secures €3.1M Seed Financing

Connecta Therapeutics, a clinical-stage biotechnology company based in Barcelona, has raised €3.1 million in Seed funding. The round was led by Clave Capital and included participation from CDTI Innvierte, Inveready, and the Prous Institute for Biomedical Research. The funding date is September 10, 2026.

What Connecta Therapeutics Does

Connecta Therapeutics develops small-molecule neuroplasticity modulators for disorders of the central nervous system. The company was founded in 2019 as a spin-off of the Prous Institute for Biomedical Research.

Its lead program, CTH120, is a potential first-in-class, disease-modifying treatment for Fragile X syndrome, a rare neurodevelopmental disorder with no approved targeted therapies. CTH120 is currently being evaluated in a Phase IIa trial in adult male patients. The company is also preparing pediatric development of CTH120 through the EU-co-funded FRAXCURE project.

Funding Details

• Round type: Seed
• Amount raised: €3,100,000
• Lead investor: Clave Capital
• Additional investors: CDTI Innvierte, Inveready, Prous Institute for Biomedical Research
• Announcement date: September 10, 2026

Why This Matters for Acquisition Watchers

Connecta Therapeutics operates in the rare neurodevelopmental disorder space, where approved targeted therapies are absent. Its lead candidate, CTH120, is already in a Phase IIa clinical trial for Fragile X syndrome, giving the company a clinical-stage asset rather than a preclinical concept. The involvement of the Prous Institute for Biomedical Research, both as a founding entity and an investor, suggests deep institutional backing and continuity from the company’s origins.

The Seed round includes a mix of venture capital and public innovation funding through CDTI Innvierte, a Spanish government-backed investment vehicle. This combination can provide both capital and validation for early-stage biotech programs.

For strategic acquirers, Connecta Therapeutics represents a potential opportunity in a therapeutic area with high unmet need. The company’s focus on neuroplasticity modulators could have broader applications beyond Fragile X syndrome, though no additional indications have been disclosed. The ongoing Phase IIa trial and planned pediatric development through FRAXCURE indicate a pipeline with near-term clinical milestones.

About the Investors

• Clave Capital led the round.
• CDTI Innvierte participated, bringing public innovation funding expertise.
• Inveready participated, adding to the syndicate.
• Prous Institute for Biomedical Research participated, reinforcing its connection as the company’s origin.

Looking Ahead

Connecta Therapeutics will likely use the Seed proceeds to support the ongoing Phase IIa trial of CTH120 in adult male patients and to prepare for pediatric development under the FRAXCURE project. As a clinical-stage company with a first-in-class candidate, it occupies a space where acquisition interest often centers on de-risked clinical assets and rare disease market potential.

No additional financial terms, valuation, or use of proceeds were disclosed in the funding announcement.